Millions of people living with HIV in low- and middle-income countries (LMICs) are facing the risk of treatment shortages following the recent funding pause for critical HIV programs. According to UNAIDS, around 28.7 million people are currently on antiretroviral treatment in LMICs, with over 83% of these medicines provided through  MPP’s licensees. These treatments have been procured, delivered, and distributed in many countries thanks to international aid, including substantial contributions from the US programs of USAID and PEPFAR. These programs have transformed the global HIV response over the past decades, saving countless lives and enabling millions to thrive in LMICs. 

Millions of lives depend on uninterrupted access to life-saving HIV therapies including half a million of children who depend on these medicines, and it is vital that we maintain the progress achieved so far so that services can deliver them to those in need. Sustained efforts and strong partnerships are essential to ensuring that no one is left behind.  

Global progress in the fight against HIV has been a collective achievement, made possible through partnerships, investments, and determination. Our priority remains to ensure that critical medicines continue to reach those who rely on them during these uncertain times. We offer our support in any way we can to the World Health Organization, governments, generic manufacturers, partners, and communities to address challenges that may arise. 

MPP’s vision of a world where everyone has timely and continued access to affordable, high-quality medicines remains steadfast. We will continue to collaborate and engage with stakeholders in the hope that essential treatments continue to reach all those who need them, now and in the future, preserving the health of people living and affected by HIV.